Showing results (41-50 of 616) with videos related to
Sort By:
Pageof 62
Clinical Advances in Hematology & Oncology : H&O|November 14, 2006
Systemic mastocytosis: current classification and novel therapeutic optionsDavid A Barbie, Daniel J DeangeloCurrent Hematologic Malignancy Reports|June 29, 2017
Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical PracticeMarlise R Luskin, Daniel J DeAngeloOncology and Therapy|July 24, 2020
A Review of Omacetaxine: A Chronic Myeloid Leukemia Treatment ResurrectedEric S Winer, Daniel J DeAngeloCurrent Hematologic Malignancy Reports|April 29, 2010
New agents for the treatment of patients with acute lymphoblastic leukemiaDaniel J DeAngelo, Richard M StoneExpert Review of Hematology|November 19, 2010
JAK2 V617F and beyond: role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasmsStephen T Oh, Jason GotlibAmerican Journal of Hematology|August 25, 2006
A patient with paroxysmal nocturnal hemoglobinuria, T cell large granular lymphocyte clonal expansion, and monoclonal gammopathy of undetermined significanceJon S Fukumoto, Jason GotlibBlood|January 18, 2013
International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosisJason Gotlib, Animesh Pardanani, Cem Akin, et al.Leukemia Research|July 25, 2025
Avapritinib versus midostaurin or cladribine in advanced systemic mastocytosis: A retrospective real-world external control studyAndreas Reiter, Jason Gotlib, Iván Álvarez-Twose, et al.Current Hematologic Malignancy Reports|August 30, 2018
Clinical Validation of KIT Inhibition in Advanced Systemic MastocytosisJohn H Baird, Jason GotlibCurrent Hematologic Malignancy Reports|April 29, 2010
Antiangiogenic therapy in myelodysplastic syndromes: is there a role?Stephen T Oh, Jason GotlibPageof 62